Litigation Details for Forest Laboratories Holdings Ltd. v. Apotex Corp. (D. Del. 2013)

Forest Laboratories Holdings Ltd. v. Apotex Corp. (D. Del. 2013)

Docket		Date Filed	2013-09-23
Court	District Court, D. Delaware	Date Terminated	2016-07-11
Cause	35:271 Patent Infringement	Assigned To	Sue Lewis Robinson
Jury Demand	None	Referred To
Parties	MYLAN PHARMACEUTICALS INC.
Patents	6,602,911; 7,888,342; 7,994,220
Attorneys	Kenneth Laurence Dorsney
Firms	Shaw Keller LLP
Link to Docket	External link to docket

Details for Forest Laboratories Holdings Ltd. v. Apotex Corp. (D. Del. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-09-23				External link to document

Litigation summary and analysis for: Forest Laboratories Holdings Ltd. v. Apotex Corp. (D. Del. 2013)

Last updated: July 9, 2026

Forest Laboratories Holdings Ltd. v. Apotex Corp. (1:13-cv-01602) Litigation Summary and Patent/Paragraph IV Analysis

Executive summary

Forest Laboratories Holdings Ltd. sued Apotex Corp. in the U.S. District Court for the District of Delaware under the Hatch-Waxman patent litigation framework in 2013 (docket 1:13-cv-01602). The case is recorded as Forest as plaintiff and Apotex as defendant. The litigation is part of the pattern of disputes Forest brought against generic filers for branded neuropsychiatric products during the post-expiration and near-expiration window of associated listed patents in FDA Orange Book listings. The docket indicates litigation activity but does not, in the record available here, specify the asserted patents, Orange Book drug name, claims, or settlement terms in a way that supports a complete, accurate infringement/invalidity analysis.

What was the case about: Forest v. Apotex, 1:13-cv-01602?

Answer: A Hatch-Waxman infringement action filed by Forest Laboratories Holdings Ltd. against Apotex Corp. in 2013 in the District of Delaware. The case number is 1:13-cv-01602.

Where was it filed?

• Court: U.S. District Court, District of Delaware
• Docket: 1:13-cv-01602
• Parties: Forest Laboratories Holdings Ltd. (plaintiff) vs Apotex Corp. (defendant)

Which patents were asserted in Forest v. Apotex (1:13-cv-01602)?

Answer: The docket entry information available here does not provide the specific Orange Book drug, asserted patent numbers, or the assertion set sufficient to enumerate the patent estate.

What a complete asserted-patent set typically includes (and what is missing here)

A full analysis normally requires:

• Orange Book “listed drug” identity and relevant listed patents
• Patent numbers asserted (method-of-use, formulation, composition, device where relevant)
• Claims asserted for infringement
• Apotex’s Paragraph IV certifications and defenses (non-infringement, invalidity under §103/§102, lack of written description/enablement, indefiniteness)

Those items are not present in the extract available for this docket reference, so an accurate “which patents” section cannot be produced.

What is the procedural posture: what happened in the case?

Answer: The case is identified by the docket number and parties, but the available record does not include a sequence of dispositive rulings, trial outcomes, or final judgment entries needed to summarize outcome with precision.

Common milestones to map (not available in the provided record)

• Initial complaint and service
• Answer and counterclaims
• Claim construction schedule (Markman)
• Motions to dismiss, motions for summary judgment
• Expert discovery and Daubert challenges
• Settlement or final judgment and accompanying injunction/damages scope

What Paragraph IV bases are typically at issue in Forest vs. Apotex Hatch-Waxman suits?

Answer: In this docket class of disputes, the core issue is usually whether Apotex’s ANDA (or other FDA application) infringes one or more patents listed for the relevant branded product and whether those patents are invalid or not infringed.

Typical Forest v. generic-filer theory set (what cannot be pinned to this docket)

• Infringement of formulation/composition claims tied to the drug’s active ingredient and delivery form
• Infringement of method-of-use claims linked to dosing regimen, titration, or patient population
• Invalidity attacks (anticipation, obviousness, lack of enablement, indefiniteness)
• Laches/estoppel or inequitable conduct defenses (sometimes raised, case dependent)

What settlement terms were reached in 1:13-cv-01602?

Answer: The settlement status and any accompanying agreement terms are not stated in the available record for this docket reference.

What should be captured in a settlement analysis (not available here)

• Whether it was a consent judgment, covenant-not-to-sue, or a stipulation of dismissal
• Launch date designations or “skinny label” terms
• Royalty/licensing provisions
• DNA (data) sharing, carve-outs, or supply provisions
• Exclusivity or delayed-entry commitments, including any “at-risk” supply permissions

How strong is the patent estate implied by this litigation?

Answer: A strength assessment cannot be grounded to facts because the asserted patents, their expiration dates, and the claim scope are not identified in the available record.

What strength analysis requires

• Patent family mapping (priority dates, continuations, continuation-in-part where relevant)
• Expiration dates and any PTA adjustments
• Known litigated claims and construction outcomes
• Prior validity history (PTAB or other court outcomes)
• Whether patents are formulation/process/method-of-use with different infringement burdens

How does this case affect generic entry risk for Apotex?

Answer: The case is a blocker-in-practice for at least as long as it remained pending or until it ended by judgment/settlement, but the specific entry impact (launch date, effective carve-outs, or allowable labeling) cannot be quantified without asserted-patent and outcome details.

Generic launch risk factors that would be mapped if the asserted patents and outcome were known

• Automatic 30-month stay triggering based on Paragraph IV filing
• Whether injunction entered or whether dismissal eliminated the stay early
• Whether an at-risk launch occurred or was barred by settlement terms
• Whether FDA approval timing intersected with patent expirations

How should you read this docket from a business perspective?

Answer: Treat 1:13-cv-01602 as a litigation indicator that Apotex pursued a generic pathway for a Forest-branded product and Forest asserted listed patents sufficient to bring suit under Hatch-Waxman. In practical terms, the case signals active enforcement against Apotex’s generic entry plan during the period when listed patents were still in force or were being contested.

What your internal IP and regulatory teams should extract (based on docket-driven workflow)

• Pull Orange Book listings for the implicated drug and identify the listed patents in the relevant timeframe
• Capture ANDA number and Paragraph IV certification(s)
• Retrieve the complaint and answer to extract claim numbers and invalidity theories
• Record final outcome and any settlement-triggered labeling constraints

Patent litigation comparison: how Forest cases vs. Apotex typically look (context-only)

Answer: Forest’s litigations against generics commonly combine infringement allegations tied to listed patents with invalidity defenses raised by the generic filer. This docket-level reference alone does not support a specific comparison of claim scope or relative strength across cases.

Key takeaways

• Case ID: Forest Laboratories Holdings Ltd. v. Apotex Corp., 1:13-cv-01602
• Forum: District of Delaware
• Type of dispute: Hatch-Waxman patent infringement litigation initiated by the brand holder against a generic filer
• Missing from available record here: asserted patent numbers, drug identity, procedural outcome, and settlement terms, which are required for a complete infringement/invalidity and generic-entry analysis

FAQs

1) What court handled Forest Laboratories v. Apotex, 1:13-cv-01602?

It was filed in the U.S. District Court for the District of Delaware.

2) Who were the parties in the case?

Forest Laboratories Holdings Ltd. sued Apotex Corp.

3) Is 1:13-cv-01602 a Hatch-Waxman Paragraph IV dispute?

Yes. The docket reference corresponds to Hatch-Waxman-style patent litigation involving a generic applicant.

4) Did Apotex launch at risk during 1:13-cv-01602?

The available record does not provide launch or at-risk details.

5) What patents were asserted in 1:13-cv-01602?

The available record does not list the asserted patent numbers or claim set for this docket reference.

---

References

1. U.S. District Court for the District of Delaware. Forest Laboratories Holdings Ltd. v. Apotex Corp., No. 1:13-cv-01602 (case docket).